380 related articles for article (PubMed ID: 26124652)
1. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
[TBL] [Abstract][Full Text] [Related]
2. Insulin dosing and outcomes among commercially insured patients with type 2 diabetes in the United States.
Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
Clin Ther; 2015 Oct; 37(10):2297-2308.e1. PubMed ID: 26341171
[TBL] [Abstract][Full Text] [Related]
3. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
[TBL] [Abstract][Full Text] [Related]
4. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
Eby EL; Boye KS; Lage MJ
J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
[TBL] [Abstract][Full Text] [Related]
5. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
6. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
[TBL] [Abstract][Full Text] [Related]
7. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
8. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
9. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
[TBL] [Abstract][Full Text] [Related]
10. Considerations for diabetes: treatment with insulin pen devices.
Cuddihy RM; Borgman SK
Am J Ther; 2013; 20(6):694-702. PubMed ID: 21768872
[TBL] [Abstract][Full Text] [Related]
11. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
Asche CV; Shane-McWhorter L; Raparla S
Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
[TBL] [Abstract][Full Text] [Related]
12. Resource utilization with insulin pump therapy for type 2 diabetes mellitus.
Lynch PM; Riedel AA; Samant N; Fan Y; Peoples T; Levinson J; Lee SW
Am J Manag Care; 2010; 16(12):892-6. PubMed ID: 21348559
[TBL] [Abstract][Full Text] [Related]
13. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
[TBL] [Abstract][Full Text] [Related]
14. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
16. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
Rashid N; McCombs JS; Schwartz E
Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
[TBL] [Abstract][Full Text] [Related]
17. The burden of diabetes mellitus for medicare beneficiaries.
Costantino ME; Stacy JN; Song F; Xu Y; Bouchard JR
Popul Health Manag; 2014 Oct; 17(5):272-8. PubMed ID: 24865764
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs.
Lokhandwala T; Smith N; Sternhufvud C; Sörstadius E; Lee WC; Mukherjee J
J Med Econ; 2016; 19(3):203-12. PubMed ID: 26473990
[TBL] [Abstract][Full Text] [Related]
19. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
Kalirai S; Duan R; Liu D; Reed BL
J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
[TBL] [Abstract][Full Text] [Related]
20. The burden of severe hypoglycemia in type 1 diabetes.
Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J
Curr Med Res Opin; 2018 Jan; 34(1):171-177. PubMed ID: 29019269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]